Close
Achema middle east
swop processing & packaging

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Symeres acquiries DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Symeres, a leading global Contract Research, Development and Manufacturing...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Purification & Filtration division manufactures filters and membranes for biopharmaceutical and medical technologies, microelectronics, food and beverage goods, and drinking water. It employs over 2,500 people worldwide and has locations in the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Solventum’s Purification & Filtration division is expected to earn almost $1 billion in revenue by 2024.

Marc Casper, chairman, president and CEO of Thermo Fisher, said: “As the trusted partner to our customers, Solventum’s Purification & Filtration business will expand and add differentiated capabilities to our bioprocessing portfolio to better serve our customers in this rapidly growing market. We look forward to welcoming our new colleagues to Thermo Fisher.”

The acquisition is scheduled to close by the end of 2025, subject to regulatory approval and usual closing conditions.

Following the transaction, Thermo Fisher’s Life Sciences Solutions sector will include the Purification & Filtration business.

Latest stories

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Symeres acquiries DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Symeres, a leading global Contract Research, Development and Manufacturing...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »